ENeura Therapeutics (Formerly Neuralieve)

About ENeura Therapeutics (Formerly Neuralieve)

eNeura Inc. is a medical technology company specializing in the development and commercialization of non-invasive, portable devices for the treatment and prevention of migraines. The company's flagship product, the SAVI Dual, is an FDA-cleared neuromodulation therapy device designed to deliver therapeutic pulses to the brain, targeting hyperactive nerves to alleviate migraine symptoms and reduce the frequency of migraine days. The device is user-friendly, requiring just a minute of use per day, and automatically records treatment history for patient convenience.

Operating in the healthcare and medical device market, eNeura primarily serves individuals suffering from migraines, a condition that affects 1 in 7 people worldwide, with a higher prevalence among women. The business model revolves around the sale of the SAVI Dual device and potentially recurring revenue from associated services or consumables.

Revenue generation is driven by direct sales to consumers, partnerships with healthcare providers, and potential reimbursement from insurance companies. The company aims to provide a cost-effective, non-pharmaceutical alternative to traditional migraine treatments, addressing a significant unmet need in the market.